ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

ClinicalTrials.gov ID: NCT04557059

Public ClinicalTrials.gov record NCT04557059. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort

Study identification

NCT ID
NCT04557059
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Enrollment
693 participants

Conditions and interventions

Interventions

  • Apalutamide Drug
  • LHRHa Drug
  • Radiotherapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 11, 2020
Primary completion
Aug 26, 2029
Completion
Aug 26, 2029
Last update posted
Apr 12, 2026

2020 – 2029

United States locations

U.S. sites
13
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
Arizona Urology Specialists Tucson Arizona 85741
Arkansas Urology Little Rock Arkansas 72211
Colorado Clinical Research Lakewood Colorado 80228
Urological Research Network Hialeah Florida 33016
First Urology, PSC Jeffersonville Indiana 47130
Michigan Institute of Urology Troy Michigan 48084
Associated Medical Professionals of Ny Syracuse New York 13210
The Urology Group Cincinnati Ohio 45212
Oregon Urology Institute Springfield Oregon 97477
MidLantic Urology Bala-Cynwyd Pennsylvania 19004
Urology Austin Austin Texas 78745
Houston Metro Urology Houston Texas 77027
Spokane Urology Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04557059, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04557059 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →